Construction and validation of a prognostic signature based on necroptosis-related genes in hepatocellular carcinoma

Peng, Yue-Ling; Wang, Lingxiao; Li, Mu-Ye; Liu, Liping; Li, Rong-Shan

doi:10.1371/journal.pone.0279744

Cited by 4 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression level of MFN2 is increased in osteosarcoma, and it can inhibit the immune system in osteosarcoma TIM. The level of ATP6V1E1 mRNA is downregulated in osteosarcoma, and the ATP6V1E1 mRNA expression dysregulation leads to immune imbalance in osteosarcoma 115,116 …”

Section: Mechanisms Of Cell Death In Osteosarcomamentioning

confidence: 99%

The role of programmed cell death in osteosarcoma: From pathogenesis to therapy

Liu,

Wang

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

Osteosarcoma (OS) is a prevalent bone solid malignancy that primarily affects adolescents, particularly boys aged 14–19. This aggressive form of cancer often leads to deadly lung cancer due to its high migration ability. Experimental evidence suggests that programmed cell death (PCD) plays a crucial role in the development of osteosarcoma. Various forms of PCD, including apoptosis, ferroptosis, autophagy, necroptosis, and pyroptosis, contribute significantly to the progression of osteosarcoma. Additionally, different signaling pathways such as STAT3/c‐Myc signal pathway, JNK signl pathway, PI3k/AKT/mTOR signal pathway, WNT/β‐catenin signal pathway, and RhoA signal pathway can influence the development of osteosarcoma by regulating PCD in osteosarcoma cell. Therefore, targeting PCD and the associated signaling pathways could offer a promising therapeutic approach for treating osteosarcoma.

show abstract

Section: Mechanisms Of Cell Death In Osteosarcomamentioning

confidence: 99%

The role of programmed cell death in osteosarcoma: From pathogenesis to therapy

Liu,

Wang

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…At present, ferroptosis, pyroptosis and necroptosis are three highly studied types of NARCD in HCC development and treatment, and these influence the fate of cells in the liver (35)(36)(37)(38)(39)(40). There are some differences and similarities among these three types of NARCD, and the key features of ferroptosis, pyroptosis and necroptosis, including the morphological and biochemical features, key regulators, and related drugs are shown in Table I.…”

Section: Introductionmentioning

confidence: 99%

Ferroptosis, pyroptosis and necroptosis in hepatocellular carcinoma immunotherapy: Mechanisms and immunologic landscape (Review)

Liu,

Yu,

Yan

et al. 2024

Int J Oncol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), one of the leading causes of cancer-related mortality worldwide, is challenging to identify in its early stages and prone to metastasis, and the prognosis of patients with this disease is poor. Treatment options for HCC are limited, with even radical treatments being associated with a risk of recurrence or transformation in the short term. Furthermore, the multi-tyrosine kinase inhibitors approved for first-line therapy have marked drawbacks, including drug resistance and side effects. The rise and breakthrough of immune checkpoint inhibitors (ICIs) have provided a novel direction for HCC immunotherapy but these have the drawback of low response rates. Since avoiding apoptosis is a universal feature of cancer, the induction of non-apoptotic regulatory cell death (NARCD) is a novel strategy for HCC immunotherapy. At present, NARCD pathways, including ferroptosis, pyroptosis and necroptosis, are novel potential forms of immunogenic cell death, which have synergistic effects with antitumor immunity, transforming immune 'cold' tumors into immune 'hot' tumors and exerting antitumor effects. Therefore, these pathways may be targeted as a novel treatment strategy for HCC. In the present review, the roles of ferroptosis, pyroptosis and necroptosis in antitumor immunity in HCC are discussed, and the relevant targets and signaling pathways, and the current status of combined therapy with ICIs are summarized. The prospects of targeting ferroptosis, pyroptosis and necroptosis in HCC immunotherapy are also considered.

show abstract

MPCD Index for Hepatocellular Carcinoma Patients Based on Mitochondrial Function and Cell Death Patterns

Wang,

Zhao,

Shu

et al. 2024

Preprint

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a highly heterogeneous cancer with a poor prognosis. During the development of cancer cells, mitochondria influence various cell death patterns by regulating metabolic pathways such as oxidative phosphorylation. However, the relationship between mitochondrial function and cell death patterns in HCC remains unclear. In this study, we used a comprehensive machine learning framework to construct a mitochondrial functional activity-associated programmed cell death index (MPCDI) based on scRNA-seq and RNA-seq data from TCGA, GEO, and ICGC datasets. The index signature was used to classify HCC patients, and studied the multi-omics features, immune microenvironment, and drug sensitivity of the subtypes. Finally, we constructed the MPCDI signature consisting of four genes (S100A9, FYN, LGALS3, and HMOX1), which was one of the independent risk factors for the prognosis of HCC patients. The HCC patients were divided into high- and low-MPCDI groups, and the immune status was different between the two groups. Patients with high MPCDI had higher TIDE scores and poorer responses to immunotherapy, suggesting that high-MPCDI patients might not be suitable for immunotherapy. By analyzing the drug sensitivity data of CTRP, GDSC, and PRISM databases, it was found that staurosporine has potential therapeutic significance for patients with high MPCDI. In summary, based on the characteristics of mitochondria function and PCD patterns, we used single-cell and transcriptome data to identify four genes and construct the MPCDI signature, which provided new perspectives and directions for the clinical diagnosis and personalized treatment of HCC patients.

show abstract

Construction and validation of a prognostic signature based on necroptosis-related genes in hepatocellular carcinoma

Cited by 4 publications

References 40 publications

The role of programmed cell death in osteosarcoma: From pathogenesis to therapy

The role of programmed cell death in osteosarcoma: From pathogenesis to therapy

Ferroptosis, pyroptosis and necroptosis in hepatocellular carcinoma immunotherapy: Mechanisms and immunologic landscape (Review)

MPCD Index for Hepatocellular Carcinoma Patients Based on Mitochondrial Function and Cell Death Patterns

Contact Info

Product

Resources

About